Arun Sanyal
Dr. Arun Sanyal is a prominent hepatologist and the director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health. He is recognized for his extensive research in liver diseases, particularly metabolic liver disorders such as metabolic dysfunction associated steatohepatitis (MASH). Recently, he gained attention for his role in a groundbreaking clinical trial that demonstrated the effectiveness of semaglutide injections in reversing severe liver disease, providing new hope for patients suffering from fatty liver disease.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 8.00 | 0.03% | +0% | 331,002,651 | 104,220 | $21,000,000 | 6,612$ |
| Totals | 1 | 331,002,651 | 104,220 | $21,000,000 | 6,612$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Arun Sanyal, M.D., director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, discusses the clinical trial involving 800 participants.
8
Saudi Arabia:
Arun Sanyal from Virginia Commonwealth University was one of the principal researchers in the trial of semaglutide.
9
United States:
Arun Sanyal, M.D., director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, discusses the clinical trial involving 800 participants.
9